Accenture Acquired in-process research and development remained flat by 0.0% to $204.33M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 29.0%, from $287.61M to $204.33M. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows a downward trend with a -7.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Acquired In-Process Research and Development (IPR&D) represents the cash paid to acquire research projects that have not...
A hallmark metric for pharmaceutical and biotech firms relying on external innovation.
cf_acquired_ipr_d| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.12B | $1.12B | $1.30B | $1.15B | $817.30M |
| YoY Change | — | +0.4% | +15.6% | -11.4% | -29.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.